Compare Avantis International Small Cap Value ETF (AVDV) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs Neurocrine Biosciences Inc — how do they compare? Avantis International Small Cap Value ETF trades at $104.56, while Neurocrine Biosciences Inc trades at $171.61 (market cap $17.30B). Which is the better fit depends on your goals.
| AVDV | NBIX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $180.55 |
52-Week Low | $80.02 | $123.10 |
Market Cap | — | $17.30B |
Enterprise Value | — | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $103.10, down 1.06% with a bearish technical signal from moving averages. Recent news highlights strong 2026 performance with international small-cap value strategies delivering 35% gains while paying dividends. The fund's commodity exposure has cooled after driving outperformance, shifting the forward setup.
The outlook remains mixed with technical indicators signaling caution but positive sentiment around international small-cap value diversification. Key risks include commodity volatility and regional economic exposure, while institutional interest grows with Farther Finance increasing holdings by 165.8% in Q4 2025.
Neurocrine Biosciences (NBIX) trades at $174.10, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and support at $173. The company demonstrates robust fundamentals with Q1 2026 revenue growth of 44% year-over-year to $811 million and consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected. Recent pipeline advancements include Phase 2 studies for crinecerfont and positive VYKAT XR data presented at ENDO 2026.
NBIX presents compelling growth prospects with analyst consensus price target of $195.75 (12% upside) and 86% buy ratings. Key opportunities include blockbuster drug performance and strategic acquisitions, while risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's current valuation at 26.5x P/E reflects growth expectations but requires continued execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
